Instead, analysis of The Cancer Genome Atlas (TCGA) database demonstrated that the PARK2 promoter was hypermethylated in select human tumors, including breast (BRCA) and prostate (PRAD) adenocarcinoma, as well as kidney cancer (KIRC), compared with normal tissues (Figure 2, A and B). Here, PRKN is linked to adenocarcinoma.